AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

Data ReadoutAmpligenPositive

AI Analysis

Summary

AIM ImmunoTech announced progress on its DURIPANC trial with Ampligen ahead of schedule, with clinical benefit readout expected in December 2026 and overall survival analysis anticipated in mid-2027.

Clinical Trial Data

Outcome Details

Clinical benefit readout expected in December 2026; overall survival analysis expected in mid-2027

Importance:6/10

Sentiment:

0.60

Ampligenpancreatic cancerclinical trialdata readoutDURIPANC

Related Companies

$AIMT

Read the original article

Published by GlobeNewswire Clinical Studies on August 3, 2026 12:33 PM

Read Original